Proteasome inhibitors suppress expression of NPM and ARF proteins

Cell Cycle

Volumn 10, Issue 22, 2011, Pages 3827-3829

  Pandit, Bulbul ^a   Gartel, Andrei L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ARF; Boretezomib; FOXM1; NPM; Proteasome inhibitors; Thiostrepton

Indexed keywords

ARF PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; MESSENGER RNA; NUCLEOPHOSMIN; PROTEASOME INHIBITOR;

GENE EXPRESSION; HELA CELL; HUMAN; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 81855189631     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.22.18211     Document Type: Short Survey

References (16)

1. Hochstrasser M. Protein degradation or regulation: Ub the judge. Cell 1996; 84:813-5; PMID:8601303; DOI:10.1016/S0092-8674(00)81058-2.
2. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68:1015-68; PMID:10872471; DOI:10.1146/annurev.biochem.68.1.1015.
3. Rubenstein EM, Hochstrasser M. Redundancy and variation in the ubiquitin-mediated proteolytic targeting of a transcription factor. Cell Cycle 2010; 9:4282-5; PMID:20980825; DOI:10.4161/cc.9.21.13741.
4. Shabek N, Ciechanover A. Degradation of ubiquitin: the fate of the cellular reaper. Cell Cycle 2010; 9:523-30; PMID:20107325; DOI:10.4161/cc.9.3. 11152.
5. Adams J. Proteasome a suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-60; PMID:15122206; DOI:10.1038/nrc1361.
6. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22:304-11; PMID:15199612; DOI:10.1081/CNV- 120030218.
7. Duensing S, Duensing A. Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget 2010; 1:6-8; PMID:21293050.
8. Pandit B, Gartel AL. Thiazole antibiotic thiostrepton synergize with bortezomib to induce apoptosis in cancer cells. PLoS ONE 2011;6:17110; PMID:21365012; DOI:10.1371/journal.pone.0017110.
9. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2011; 2:209-21; PMID:21444945.
10. Fulda S. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link. Oncotarget 2011; 2:418-21; PMID:21789791.
11. Bhat UG, Halasi M, Gartel AL. FoxM1 is a general target for proteasome inhibitors. PLoS ONE 2009; 4:6593; PMID:19672316; DOI:10.1371/journal.pone. 0006593.
12. Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS ONE 2009; 4:5592; PMID:19440351; DOI:10.1371/journal.pone.0005592.
13. Pollice A, Sepe M, Villella VR, Tolino F, Vivo M, Calabrò V, et al. TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation. Oncogene 2007; 26:5154-62; PMID:17334400; DOI:10.1038/sj.onc.1210313.
14. ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25:1258-71; PMID:15684379; DOI:10.1128/MCB.25.4. 1258-71.2005.
15. Gartel AL. A new target for proteasome inhibitors: FoxM1. Expert Opin Investig Drugs 2010; 19:235-42; PMID:20074015; DOI:10.1517/13543780903563364.
16. Halasi M, Gartel AL. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 2009; 8:1966-7; PMID:19411834; DOI:10.4161/cc.8.12.8708.